Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.460
+0.010 (0.69%)
Apr 28, 2026, 10:03 AM EDT - Market open
Marker Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Marker Therapeutics stock has a target of 10, which predicts a 584.93% increase from the current stock price of 1.46.
Price Target: $10 (+584.93%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 8, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Marker Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +584.93% | Dec 8, 2025 |
| WBB Securities | WBB Securities | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +756.16% | Apr 1, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +447.95% | Mar 5, 2025 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $11 → $19 | Strong Buy | Maintains | $11 → $19 | +1,201.37% | Oct 21, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +653.42% | Apr 30, 2024 |
Financial Forecast
Revenue This Year
2.75M
from 3.55M
Decreased by -22.49%
Revenue Next Year
28.49M
from 2.75M
Increased by 936.27%
EPS This Year
-1.01
from -0.79
EPS Next Year
-1.04
from -1.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 6.1M | 34.5M | ||||
| Avg | 2.7M | 28.5M | ||||
| Low | n/a | 22.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 71.3% | 1,155.0% | ||||
| Avg | -22.5% | 936.3% | ||||
| Low | - | 719.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.64 | -0.20 | |||
| Avg | -1.01 | -1.04 | |||
| Low | -1.50 | -1.48 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.